VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
ANIP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
ANIPANI Pharmaceuticals, Inc.
$74.43$1.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksANIPP/E History

ANIP logoANI Pharmaceuticals, Inc. (ANIP) P/E Ratio History

Deep Value

Trading at 22.4x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2006–2026

Current P/E (TTM)
22.4x
-94% vs 5Y avg
5Y Avg P/E
351.2x
Median 61.3x
5Y Percentile
10th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
22.4x
Min17.9xMedian61.3xMax5654.0x
TTM EPS$4.83
Price$74.43
Earnings Yield4.46%
EPS Growth (1Y)419.2%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of September 24, 2026, ANI Pharmaceuticals, Inc. (ANIP) trades at a price-to-earnings ratio of 22.4x, with a stock price of $74.43 and trailing twelve-month earnings per share of $4.83.

The current P/E is 94% below its 5-year average of 351.2x. Over the past five years, ANIP's P/E has ranged from a low of 17.9x to a high of 5654.0x, placing the current valuation at the 10th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.7x, ANIP is roughly in line with its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.

Relative to the broader market, ANIP trades roughly in line with the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ANIP DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ANIP Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
22.4vs23.7
-5%
In Line with Sector
vs. S&P 500
22.4vs25.3
-12%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 419% EPS growth (1Y)

ANIP P/E vs Peers

Complex generics and injectables peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
AMRX logoAMRXAmneal Pharmaceuticals, Inc.
$6B87.9-+158%
LNTH logoLNTHLantheus Holdings, Inc.
$7B29.3--22%
PAHC logoPAHCPhibro Animal Health Corporation
$1B28.73.84Best+1883%Best
HI logoHIHillenbrand, Inc.
$2B52.4-+120%
MCK logoMCKMcKesson Corporation
$105B22.9Lowest-+49%
CAH logoCAHCardinal Health, Inc.
$52B30.6-+325%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ANIP Historical P/E Data (2006–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q2-$82.78$4.6317.9x-92%
FY2026 Q1-$76.90$3.9419.5x-92%
FY2025 Q4Dec 31 2025$78.94$3.3523.6x-90%
FY2025 Q3-$91.60$1.6356.2x-76%
FY2024 Q2Jun 30 2024$63.68$1.2351.8x-77%
FY2024 Q1Mar 31 2024$69.13$1.7040.7x-82%
FY2023 Q4Dec 31 2023$55.14$0.9359.2x-74%
FY2023 Q3Sep 30 2023$58.06$0.6194.8x-59%
FY2019 Q4-$61.67$0.48128.5x-44%
FY2019 Q3Sep 30 2019$72.88$1.3554.0x-76%
FY2019 Q2Jun 30 2019$82.20$1.4556.7x-75%
FY2019 Q1Mar 31 2019$70.54$1.1561.3x-73%
FY2018 Q4Dec 31 2018$45.02$1.3034.6x-85%
FY2018 Q3Sep 30 2018$56.54$0.015654.0x+2362%
FY2017 Q3Sep 30 2017$52.49$0.6482.4x-64%
FY2017 Q2Jun 30 2017$46.80$0.46102.4x-55%
FY2017 Q1Mar 31 2017$49.51$0.33151.3x-34%
FY2016 Q4Dec 31 2016$60.62$0.35174.6x-24%
FY2016 Q3Sep 30 2016$66.35$0.6996.2x-58%
FY2016 Q2-$55.82$0.8664.9x-72%
FY2016 Q1-$33.66$1.0731.5x-86%
FY2015 Q4-$45.13$1.3333.9x-85%
FY2015 Q3Sep 30 2015$39.51$2.9013.6x-94%
FY2015 Q2-$62.05$3.1020.0x-91%
FY2015 Q1-$62.55$2.5824.2x-89%
FY2014 Q4Dec 31 2014$56.39$2.5322.3x-90%
FY2014 Q3-$28.28$1.0726.4x-88%
FY2014 Q2Jun 30 2014$34.44$0.8640.0x-83%
FY2007 Q3Sep 30 2007$208.80$6.8130.7x-87%
FY2007 Q2Jun 30 2007$228.24$7.8629.0x-87%
FY2007 Q1Mar 31 2007$214.92$7.3829.1x-87%
FY2006 Q4Dec 31 2006$99.72$4.2023.7x-90%

Average P/E for displayed period: 229.7x

Export Data
Consensus & Technical Research Suite
Open ANIP Terminal

ANIP Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

20+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ANIP — Frequently Asked Questions

Quick answers to the most common questions about buying ANIP stock.

What is ANIP's P/E ratio?

ANI Pharmaceuticals, Inc. (ANIP) trailing twelve-month P/E ratio is 22.4x, based on TTM diluted EPS of $4.83. The 5-year average P/E is 351.2x and the historical range spans 17.9x to 5654.0x.

Is ANIP stock overvalued or undervalued?

ANIP trades at 22.4x P/E, below its 5-year average of 351.2x. At the 10th percentile of its historical range (17.9x–5654.0x), the stock is priced at a discount to its own history.

Is ANIP stock expensive?

No, ANIP is not expensive on a historical basis. The current P/E of 22.4x is below the 5-year average of 351.2x and sits at the 10th percentile of its valuation range.

What is ANIP's historical P/E range?

Over the past 5 years, ANIP's P/E ratio has ranged from 17.9x to 5654.0x, with a median of 61.3x and an average of 351.2x. The current P/E of 22.4x places the stock at the 10th percentile of this range. Full historical data spans 2006–2026.

How does ANIP's P/E compare to the S&P 500?

ANIP trades at 22.4x P/E versus the S&P 500 median of 25.3x. The 11% discount to the market suggests lower growth expectations or perceived higher risk.

How does ANIP's valuation compare to Healthcare peers?

ANI Pharmaceuticals, Inc. P/E of 22.4x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ANIP's PEG ratio?

ANIP PEG ratio is N/A, based on a P/E of 22.4x and EPS growth of 419.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ANIP's earnings yield?

ANIP earnings yield is 4.46%, the inverse of its 22.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ANIP P/E Ratio History (2006–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current17.9x
Period Avg351.2x
Range17.9x - 5654.0x
Change-72%
20 quartersJun 30, 2016 - Jun 30, 2026